Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Bristol-Myers Squibb
(NY:
BMY
)
58.04
-0.10 (-0.17%)
Official Closing Price
Updated: 7:00 PM EDT, Sep 29, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
10,928,796
Open
58.18
Bid (Size)
57.86 (1)
Ask (Size)
59.50 (1)
Prev. Close
58.14
Today's Range
57.87 - 58.46
52wk Range
57.61 - 81.44
Shares Outstanding
2,222,113,553
Dividend Yield
3.38%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Pharma Giants Shift Stance, Embrace Medicare Negotiations Amid Rising Drug Costs
September 28, 2023
AstraZeneca Plc (NASDAQ: AZN), Bristol Myers Squibb & Co (NYSE: BMY), and Boehringer Ingelheim are willing to participate in the initial round of Medicare drug price negotiation
Via
Benzinga
3 Dividend Stocks to Buy and Hold Until Retirement
September 28, 2023
Together, these stocks can also help diversify your portfolio by giving you exposure to different industries.
Via
The Motley Fool
Performance
YTD
-19.68%
-19.68%
1 Month
-5.86%
-5.86%
3 Month
-9.92%
-9.92%
6 Month
-16.72%
-16.72%
1 Year
-18.36%
-18.36%
More News
Read More
Bristol-Myers Squibb Unusual Options Activity For September 27
September 27, 2023
Via
Benzinga
Bristol Myers Squibb to Report Results for Third Quarter 2023 on October 26, 2023
September 26, 2023
From
Bristol Myers Squibb
Via
Business Wire
Argenx's 28% Surge & Promising Product Propel Investor Confidence
September 25, 2023
Via
MarketBeat
Looking Into Bristol-Myers Squibb's Recent Short Interest
September 18, 2023
Via
Benzinga
2 Undervalued Dividend Stocks to Buy Now
September 13, 2023
Via
The Motley Fool
Investigational Immunotherapy Treatments Offering Promise in Treating Pancreatic Cancer as Risk Factors Rise
September 26, 2023
Via
FinancialNewsMedia
3 Artificial Intelligence (AI) Stocks That Could Soar More Than Nvidia, According to Wall Street
September 25, 2023
Via
The Motley Fool
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Beware! 3 Healthcare Stocks Waving Massive Red Flags Right Now.
September 24, 2023
Via
InvestorPlace
Week In Review: Everest Acquires Novel Autoimmune Therapy In $132 Million Agreement
September 23, 2023
Via
Talk Markets
Bristol Myers' Lead Cancer Drug Opdivo Regime Meets Primary Goal In Phase 3 Lung Cancer Study
September 22, 2023
Via
Benzinga
Bristol Myers Squibb Announces Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo Significantly Improves Event-Free Survival in Patients with Resectable Non-Small Cell Lung Cancer
September 22, 2023
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Announces Dividend
September 20, 2023
From
Bristol Myers Squibb
Via
Business Wire
Anemia Advantage For GSK's Blood Cancer Therapy Could Influence Market Share Despite Incyte's Jakafi Comparison
September 18, 2023
Via
Benzinga
Exposures
Product Safety
10 Health Care Stocks Whale Activity In Today's Session
September 15, 2023
Via
Benzinga
The 3 Most Undervalued Pharma Stocks to Buy in September 2023
September 14, 2023
Via
InvestorPlace
Bristol-Myers Squibb Plans To Double Clinical Pipeline Platforms To Support Long-Term Sustainable Growth
September 14, 2023
Via
Benzinga
Bristol Myers Squibb Highlights Advancing Pipeline and Differentiated Research Platforms to Support Long-Term Sustainable Growth at R&D Day
September 14, 2023
From
Bristol Myers Squibb
Via
Business Wire
The Next Walgreens CEO? My Top 3 Picks to Replace Roz Brewer.
September 13, 2023
Via
InvestorPlace
Recent Pullback Buying Opportunity For Blood Cancer Firm Geron: Goldman Sachs
September 12, 2023
Via
Benzinga
Bristol Myers Squibb's Opdivo Plus Yervoy Combo Shows Durable, Long-Term Survival In Lung Cancer Patients
September 11, 2023
Via
Benzinga
How A Small Indian Firm Firm Was Pulled Into A Legal Battle with Big Pharma Over A Cancer Drug
September 11, 2023
Via
Benzinga
Six-Year Outcomes from Phase 3 CheckMate -227 Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipilimumab) in the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer
September 11, 2023
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb’s Investigational LPA1 Antagonist Reduces Rate of Lung Function Decline in Progressive Pulmonary Fibrosis Cohort of Phase 2 Study
September 09, 2023
From
Bristol Myers Squibb
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.